MAHONEY DAVID L sold $12.3M of CORT (indirect holdings)

MAHONEY DAVID L sold 103,606 indirectly-held shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $118.25 ($117.47–$119.64, $12.25M total) across 4 trades on 2026-08-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MAHONEY DAVID L
Published Aug 20, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 8:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Bearish
medium confidence
Mentioned
$CORT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTBearishLow
01

Why it matters

The director's $12.3M sale may trigger short‑term sell pressure but could be neutral if viewed as routine.

02

Market read

Primary insider sale; modest materiality for traders monitoring biotech stocks.

03

What to watch

Sale executed via pre‑arranged 10b5‑1 plan, which may be routine and not reflective of new information.

Relevance 6/10Novelty 7/10Timing: filing on Aug 20, reflects recent Aug 18 sale

Background

SEC Form 4 filing discloses insider transactions; provides transparent view of insider holdings.

Company-level read

Ticker impact

$CORTBearishMedium confidence
Context

Director David L. Mahoney sold 103,606 shares for $12.3M on Aug 18 via a 10b5‑1 plan.

Expected impact

Downward pressure on CORT price in the short term.

Evidence & confidence

Large $12M sale by a key insider suggests potential concerns about future prospects.

Market effects

May weigh on other small‑cap biotech stocks as insider activity is monitored.

Limited to US biotech sector; no broader regional effect.

Minimal global impact beyond niche biotech investors.

Counterpoint

Insider could be diversifying portfolio; sale does not necessarily imply negative fundamentals.

Key entities

  • Corcept Therapeutics Inc.

    Biopharmaceutical company developing therapies for endocrine disorders.

  • David L. Mahoney

    Director of Corcept Therapeutics who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.